Loading
A phase 2 trial of Flotufolastat F-18 in Prostate cancer, run by AdventHealth, now recruiting.
PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence is a phase 2 interventional study registered as NCT06617481 by AdventHealth, with 30 participants planned, started 2024-09-20 and due to reach its primary completion in 2027-09-05. Interventions recorded: 18F-rhPSMA-7.3 (Posluma). Conditions recorded: Prostate Cancer (Post Prostatectomy).
Linked to the drug Flotufolastat F-18 because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Flotufolastat F-18, Prostate cancer and the tag pipeline.
Shares Biochemical recurrence of prostate cancer, Prostate cancer and the tag pipeline.
Shares Biochemical recurrence of prostate cancer, Prostate cancer and the tag pipeline.
Shares Biochemical recurrence of prostate cancer, Prostate cancer and the tag pipeline.
Shares Flotufolastat F-18, Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/